Characterization of a factor IX variant with a glycine207 to glutamic acid mutation.
Factor IXTaipei9 is a factor IX variant from a hemophilia B patient with reduced levels of circulating protein molecules (cross-reacting material reduced, CRM). This variant contained a glycine (Gly) to glutamic acid (Glu) substitution at the 207th codon of mature factor IX. The functional consequences of the Gly-->Glu mutation in factor IXTaipei9 (IXG207E) were characterized in this study. Plasma-derived IXG207E exhibited a mobility similar to that of normal factor IX on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Its specific activity was estimated to be 3.5% that of the purified normal factor IX in a one-stage partial thromboplastin time assay (aPTT). Cleavage of factor IXG207E by factor XIa or factor VIIa-tissue factor complex appeared to be normal. When the calcium-dependent conformational change was examined by monitoring quenching of intrinsic fluorescence, both normal factor IX and IXG207E exhibited equivalent intrinsic fluorescence quenching. Activated factor IXG207E (IXaG207E) also binds antithrombin III equally as well as normal factor IXa. However, aberrant binding of the active site probe p-aminobenzamidine was observed for factor XIa-activated factor IXG207E, indicating that the active site pocket of the heavy chain of factor IXaG207E was abnormal. Moreover, the rate of activation of factor X by factor IXaG207E, as measured in a purified system using chromogenic substrates, was estimated to be 1/40 of that of normal factor IXa. A computer-modeled heavy-chain structure of factor IXa predicts a hydrophobic environment surrounding Gly-207 and this Gly forms a hydrogen bound to the active site serine-365. The molecular mechanism of the Gly-->Glu mutation in factor IXTaipei9 might result in the alteration of the microenvironment of the active site pocket which renders the active site serine-365 inaccessible to its substrate.
Lin
S W
SW
Graduate Institute of Medical Technology, National Taiwan University, School of Medicine, Taipei, Republic of China.
Lin
C N
CN
Hamaguchi
N
N
Smith
K J
KJ
Shen
M C
MC
D001550:Benzamidines / Q000378:metabolism; D001665:Binding Sites; D002118:Calcium / Q000494:pharmacology; D003062:Codon; D003198:Computer Simulation; D004591:Electrophoresis, Polyacrylamide Gel; D005164:Factor IX / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D015942:Factor VIIa / Q000378:metabolism; D005170:Factor X / Q000378:metabolism; D015945:Factor XIa / Q000494:pharmacology; D005971:Glutamates / Q000235:genetics*; D018698:Glutamic Acid; D005998:Glycine / Q000235:genetics*; D002836:Hemophilia B / Q000235:genetics*; D006801:Humans; D008297:Male; D008958:Models, Molecular; D009154:Mutation; D010314:Partial Thromboplastin Time; D013624:Taiwan
D001550:Benzamidines; D003062:Codon; D005971:Glutamates; D018698:Glutamic Acid; C006500:4-aminobenzamidine; D005164:Factor IX; D005170:Factor X; D015942:Factor VIIa; D015945:Factor XIa; D002118:Calcium; D005998:Glycine